Literature DB >> 12694990

Rationale and evidence for the use of oxcarbazepine in neuropathic pain.

Enrique Carrazana1, Imao Mikoshiba.   

Abstract

Oxcarbazepine is a second-generation antiepileptic drug (AED) with proven efficacy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. The overlap between the underlying pathophysiologic mechanisms of some epilepsy models and neuropathic pain models supports the rationale for using certain AEDs in the treatment of neuropathic pain. Several AEDs have reportedly produced analgesia in a range of neuropathic pains, including painful diabetic neuropathy (PDN) and post-herpetic neuralgia. Increasing evidence suggests that oxcarbazepine can provide significant analgesia in several neuropathic pain conditions, including trigeminal neuralgia and PDN, and is also may be effective in treating neuropathic pain refractory to other AEDs, such as carbamazepine and gabapentin. The analgesic effects of oxcarbazepine, and its generally improved safety and tolerability profile compared with other standard AEDs, suggests that oxcarbazepine will be an important addition to the neuropathic pain armamentarium. The rationale and evidence to support the efficacy of oxcarbazepine are presented here.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694990     DOI: 10.1016/s0885-3924(03)00067-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  8 in total

Review 1.  [Drug therapy of back pain].

Authors:  M A Rauschmann; D von Stechow
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

2.  Treatment of Neuropathic Pain.

Authors:  Matthew T Mendlik; Tanya J Uritsky
Journal:  Curr Treat Options Neurol       Date:  2015-12       Impact factor: 3.598

3.  Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap.

Authors:  Jamil Poletti-Jabbour; Andrés Wiegering-Rospigliosi; Reneé Pereyra-Elías; Carmen Cecilia Elías-Barrera
Journal:  Eur J Clin Pharmacol       Date:  2016-04-29       Impact factor: 2.953

Review 4.  Treatment of painful polyneuropathies.

Authors:  Bruce Nicholson
Journal:  Curr Pain Headache Rep       Date:  2005-06

Review 5.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Oxcarbazepine for neuropathic pain.

Authors:  Muke Zhou; Ning Chen; Li He; Mi Yang; Cairong Zhu; Fengbo Wu
Journal:  Cochrane Database Syst Rev       Date:  2017-12-02

7.  Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.

Authors:  C Solaro; D Restivo; G L Mancardi; P Tanganelli
Journal:  Neurol Sci       Date:  2007-06-30       Impact factor: 3.307

8.  Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study.

Authors:  Ariel Berger; Alesia Sadosky; Ellen Dukes; John Edelsberg; Gerry Oster
Journal:  BMC Neurol       Date:  2012-03-06       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.